Biotech's Role In Rebuilding Big Pharma's Neglected Antibiotic Pipeline
Executive Summary
Antibiotic resistance has become a key market opportunity, but Big Pharma is poorly positioned to take advantage. Having all but abandoned antibiotic drug development at least a decade ago to smaller companies able to take on the risk, major drugmakers now look to those firms as a resource to revive their pipelines. But there may not be much to choose from.
You may also be interested in...
FDA's Pending HAP/VAP Guidance Could Further Dampen Antibiotic Drug Development
FDA's pending guidance on clinical trials for antibiotics to treat hospital- and ventilator-acquired pneumonia can't help but add a measure of stability to the uncertain regulatory environment in the field, but stakeholders fear that when the clouds part, the view will be of a very high bar.
FDA's Pending HAP/VAP Guidance Could Further Dampen Antibiotic Drug Development
FDA's pending guidance on clinical trials for antibiotics to treat hospital- and ventilator-acquired pneumonia can't help but add a measure of stability to the uncertain regulatory environment in the field, but stakeholders fear that when the clouds part, the view will be of a very high bar.
Tetraphase's Broad-Spectrum Antibiotic Candidate Makes A Good Showing At ICAAC
The Boston area start-up aims to offer a "franchise of antibiotics" based on its synthetic tetracycline platform.